Trial Profile
A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs DLX 105 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Biomarker
- 30 Jul 2012 Planned End Date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 16 May 2012 New trial record